Part D drug price “negotiation” comes at cost of jobs, investment, cures Update: The House passed the Inflation Reduction Act on Friday, Aug. 12. This past weekend, the U.S. Senate passed the Inflation Reduction Act. Included in the law is a provision that gives... Continue Reading
NCBIO stands in solidarity with patient advocates and industry leaders in opposing the Centers for Medicare and Medicaid Services’ draft proposal to restrict coverage for current and future Alzheimer's drugs targeting beta amyloid, a known hallmark of the disease. Restricting coverage is a... Continue Reading
This post originally appeared on the website of the Environmental Paper Network. A serious approach to addressing climate change must include the proactive elimination of unnecessary paper consumption. Paper is an important and useful material that should be produced and consumed in a... Continue Reading
During a busy week in Congress, Democrats included a change to the Orphan Drug Tax Credit that would negatively impact research on rare diseases affecting millions of Americans. The U.S. House of Representatives has several committees marking up the Senate’s $3.5 trillion budget... Continue Reading
BIO: Where things stand with TRIPS waiver It’s been a while since we’ve talked about what’s going on at the WTO. Here’s the latest news—and why the proposed waiver of vaccine IP is still a bad idea. The status: The World Trade Organization is still... Continue Reading
BIO: How the PASTEUR Act would support antibiotic R&D The PASTEUR Act, legislation designed to make research and development of new antibiotics economically viable, was reintroduced in Congress last week with bipartisan support. Here’s what it would do and why it... Continue Reading
Government price fixing for U.S. medicines will cost lives, jobs, innovation Legislation that fixes prices for prescription medicines would limit patients’ access to new treatments while doing nothing to lower prices at the pharmacy counter, according to a new analysis released by... Continue Reading
BIO President and CEO Michelle McMurry-Heath, M.D., Ph.D., sent a letter April 19 to U.S. Trade Representative Ambassador Katherine Tai to explain why the WTO’s proposed “TRIPS waiver” would have global health and economic consequences as the pandemic rages on. India, South... Continue Reading
A new executive order from the Trump administration that slashes Medicare payments to hospitals and physicians for certain medicines will hurt patients’ access to care and financially stress already overburdened hospitals and innovation-based pharmaceutical companies, according to NCBIO, the... Continue Reading
